Advertisement

The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan

Published:September 15, 2022DOI:https://doi.org/10.1016/j.vhri.2022.06.006

      Highlights

      • To prevent cervical cancer, 2 strategies are used in combination: cervical screening and human papillomavirus (HPV) vaccination. HPV vaccination offers primary prevention of HPV-related precancers and cancers; it also protects against genital warts. Since December 2018, the Taiwanese government has provided the bivalent HPV vaccine free of charge to girls in the first year of junior high school (aged 13 years) as part of the National Immunization Program. A new nonavalent vaccine has become available.
      • The cost-effectiveness of nonavalent HPV vaccination in Taiwan has been evaluated once to date, but the static cohort model used could not account for herd immunity and likely underestimated the effectiveness of the vaccines. The objectives of this study were to assess the public health impact and to estimate the cost-effectiveness of introduction of the nonavalent vaccine into the National Immunization Program in Taiwan, taking herd immunity into account via a dynamic transmission model.
      • Introducing a 2-dose nonavalent vaccination program for girls aged 13 to 14 years in Taiwan would reduce the incidence and costs associated with cervical cancer, precancerous lesions, and genital warts caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared with bivalent vaccination. The analysis also showed that the nonavalent HPV vaccination strategy was highly cost-effective in Taiwan compared with the bivalent vaccination strategy.

      Abstracts

      Objectives

      This study aimed to estimate the epidemiologic and economic impact of a nonavalent human papillomavirus (HPV) vaccination program for 13- to 14-year-old females compared with that of the bivalent vaccine in Taiwan.

      Methods

      A previously developed dynamic transmission model for the nonavalent HPV vaccine was adapted to the Taiwan setting. The natural history of cervical cancer and genital warts was simulated by the HPV model assuming an 80% vaccination coverage rate in girls aged 13 to 14 years of age with a 2-dose schedule for the nonavalent and bivalent HPV vaccines. A lifetime duration of vaccine protection was assumed for the HPV vaccine types.

      Results

      The model estimated that the nonavalent HPV vaccine would prevent an additional 15 951 cervical cancer cases, 6600 cervical cancer-related deaths, 176 702 grade 2 or grade 3 cervical intraepithelial neoplasia cases, 103 959 grade 1 cervical intraepithelial neoplasia cases, and 1 115 317 genital warts cases compared with the bivalent HPV vaccine. The nonavalent HPV vaccination program was projected to cost an additional New Taiwan dollars (NTD) 675.21 per person and to produce an additional 0.00271 quality-adjusted life-year per person over 100 years compared with the bivalent HPV vaccine. Thus, the incremental cost-effectiveness ratio of the nonavalent HPV vaccine versus the bivalent HPV vaccine was NTD 249 462/quality-adjusted life-year.

      Conclusions

      A nonavalent HPV vaccination program for 13- to 14-year-old girls would have additional public health and economic impacts and would be highly cost-effective compared with the bivalent HPV vaccine, relative to per capita gross domestic product, which is estimated at NTD 746 526 for Taiwan.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Value in Health Regional Issues
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Genital HPV infection—fact sheet. CDC.
        http://www.cdc.gov/std/hpv/stdfact-hpv.htm
        Date accessed: October 12, 2017
      2. FDA COVID-19 response. https://www.fda.gov. US Food & Drug Administration. Accessed November 2, 2017.

      3. Human papillomavirus (HPV) and cervical cancer. World Health Organization.
        • Serrano B.
        • Brotons M.
        • Bosch F.X.
        • Bruni L.
        Epidemiology and burden of HPV-related disease.
        Best Pract Res Clin Obstet Gynaecol. 2018; 47: 14-26
        • Lai C.-H.
        • Huang H.-J.
        • Hsueh S.
        • et al.
        Human papillomavirus genotype in cervical cancer: a population-based study.
        Int J Cancer. 2007; 120: 1999-2006
      4. Cancer registry annual report Health Promotion Administration. Ministry of Health and Welfare. Republic of China.
        • Chow I.H.-I.
        • Tang C.-H.
        • You S.-L.
        • et al.
        Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
        Br J Cancer. 2010; 103: 1773-1782
        • Merck & Co., Inc
        Merck’s investigational 9-valent HPV vaccine, V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types in phase III study. Merck.
        • Elbasha E.H.
        • Dasbach E.J.
        Impact of vaccinating boys and men against HPV in the United States.
        Vaccine. 2010; 28: 6858-6867
        • Elbasha E.H.
        • Dasbach E.J.
        • Insinga R.P.
        Model for assessing human papillomavirus vaccination strategies.
        Emerg Infect Dis. 2007; 13: 28-41
        • Haeussler K.
        • Marcellusi A.
        • Mennini F.S.
        • et al.
        Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic bayesian methodology: the BEST II study.
        Value Health. 2015; 18: 956-968
        • Van Effelterre T.
        • Hogea C.
        • Taylor S.
        Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom [retracted in: Van Effelterre TP, Hogea C, Taylor SM. Hum Vaccin Immunother. 2014;10(9):2776].
        Hum Vaccin Immunother. 2014; 10: 1794
        • Chesson H.W.
        • Markowitz L.E.
        • Hariri S.
        • Ekwueme D.U.
        • Saraiya M.
        The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model.
        Hum Vaccin Immunother. 2016; 12: 1363-1372
        • Dasbach E.J.
        • Insinga R.P.
        • Yang Y.C.
        • Pwu R.-F.
        • Lac C.
        • Elbasha E.H.
        The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
        Asian Pac J Cancer Prev. 2008; 9: 459-466
        • Demarteau N.
        • Tang C.-H.
        • Chen H.-C.
        • Chen C.-J.
        • Van Kriekinge G.
        Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
        Value Health. 2012; 15: 622-631
        • Liu P.-H.
        • Hu F.-C.
        • Lee P.-I.
        • Chow S.-N.
        • Huang C.-W.
        • Wang J.-D.
        Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.
        BMC Health Serv Res. 2010; 10: 11
        • Tang C.-H.
        • Cheng W.F.
        • Jiang J.-H.
        • et al.
        Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan.
        Asian Pac J Cancer Prev. 2019; 20: 1377-1387
        • Largeron N.
        • Petry K.U.
        • Jacob J.
        • Bianic F.
        • Anger D.
        • Uhart M.
        An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.
        Expert Rev Pharmacoecon Outcomes Res. 2017; 17: 85-98
      5. Ann Her Medical Care Cooperation Ann Her Hospital.
        http://www.ah-hosp.com.tw/Expense.php
        Date accessed: March 1, 2017
      6. Annual report of cause of death. Ministry of Health and Welfare.
        • Kim C.J.
        • Kim B.G.
        • Kim S.C.
        • et al.
        Sexual behavior of Korean young women: preliminary study for the introducing of HPV prophylactic vaccine.
        Korean J Gynecol Oncol. 2007; 18 (128): 209
      7. Health and welfare database. Health and Welfare Data Science Center (HWDC).
      8. Cervical cancer screening registry system annual report Health Promotion Administration. Ministry of Health and Welfare. Republic of China.
        • Ault K.A.
        • Future II, S.G.
        Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
        Lancet. 2007; 369: 1861-1868
        • Garland S.M.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • et al.
        Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
        N Engl J Med. 2007; 356: 1928-1943
        • Giuliano A.R.
        • Palefsky J.M.
        • Goldstone S.
        • et al.
        Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
        N Engl J Med. 2011; 364: 401-411
        • Joura E.A.
        • Giuliano A.R.
        • Iversen O.E.
        • et al.
        A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
        N Engl J Med. 2015; 372: 711-723
        • Joura E.A.
        • Leodolter S.
        • Hernandez-Avila M.
        • et al.
        Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
        Lancet. 2007; 369: 1693-1702
        • Palefsky J.M.
        • Giuliano A.R.
        • Goldstone S.
        • et al.
        HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
        N Engl J Med. 2011; 365: 1576-1585
        • Institute of Medicine
        Division of Health Promotion and Disease Prevention, Committee to Study Priorities for Vaccine Development.
        in: Stratton K.R. Durch J.S. Lawrence R.S. Vaccines for the 21st Century: A Tool for Decisionmaking. National Academies Press, Washington, DC2000
      9. Myers E, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Abstract No. 390.2. Mexico City; 2004.

        • Sanders G.D.
        • Taira A.V.
        Cost-effectiveness of a potential vaccine for human papillomavirus.
        Emerg Infect Dis. 2003; 9: 37-48
        • Crowe E.
        • Pandeya N.
        • Brotherton J.M.
        • et al.
        Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.
        BMJ. 2014; 348 (g1458)
      10. Specific diagnosis and treatment laboratory examination - circulative function examination (18001-18043). NHI.
        • Andersen B.L.
        Stress and quality of life following cervical cancer.
        J Natl Cancer Inst Monogr. 1996; 21: 65-70
        • Gold M.R.
        • Franks P.
        • McCoy K.I.
        • Fryback D.G.
        Toward consistency in cost-utility analyses: using national measures to create condition-specific values.
        Med Care. 1998; 36: 778-792
        • Wenzel L.
        • DeAlba I.
        • Habbal R.
        • et al.
        Quality of life in long-term cervical cancer survivors.
        Gynecol Oncol. 2005; 97: 310-317
      11. Vaccination service. Office of Student Affairs NTU.
        https://osa.ntu.edu.tw/en
        Date accessed: March 1, 2017
        • Golicki D.
        • Niewada M.
        • Jakubczyk M.
        • Wrona W.
        • Hermanowski T.
        Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study.
        Pol Arch Med Wewn. 2010; 120: 276-281
        • WHO, Murray CJL
        Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis.
        Switzerland: WHO, Geneva2003
      12. Cancer registry annual report. BC Cancer Agency.
      13. GDP per capita in Taiwan. Focus Economics.
        • Gilbert J.A.
        • Meyers L.A.
        • Galvani A.P.
        • Townsend J.P.
        Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy.
        Epidemics. 2014; 6: 37-45